RefCheck Maintenance Notice

On Monday, December 3, 2018, from 16:00-18:00 EST, RefCheck will be undergoing maintenance. RefCheck is the process where, during copyediting, all references are extracted from the manuscript file, parsed, matched against various databases (eg, PubMed and CrossRef), and automatically corrected. For more information on RefCheck, please visit our Knowledge Base.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 29.06.15 in Vol 4, No 2 (2015): Apr-Jun

This paper is in the following e-collection/theme issue:

Works citing "Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.4320):

(note that this is only a small subset of citations)

  1. Sheil F, Donohoe CL, King S, O’Toole D, Cunningham M, Cuffe S, Ravi N, Reynolds JV. Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?. World Journal of Surgery 2018;42(5):1485
    CrossRef
  2. Kuipers EJ, Spaander MC. Natural History of Barrett’s Esophagus. Digestive Diseases and Sciences 2018;63(8):1997
    CrossRef
  3. Jelvehgaran P, Alderliesten T, Georgiou G, Meijer SL, Bloemen PR, Kodach LL, van Laarhoven HWM, van Berge Henegouwen MI, Hulshof MCCM, Rasch CRN, van Leeuwen TG, de Boer JF, de Bruin M, van Herk M. Feasibility of using optical coherence tomography to detect radiation-induced fibrosis and residual cancer extent after neoadjuvant chemo-radiation therapy: an ex vivo study. Biomedical Optics Express 2018;9(9):4196
    CrossRef
  4. Noordman BJ, Verdam MGE, Lagarde SM, Shapiro J, Hulshof MCCM, van Berge Henegouwen MI, Wijnhoven BPL, Nieuwenhuijzen GAP, Bonenkamp JJ, Cuesta MA, Plukker JTM, Spillenaar Bilgen EJ, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Annals of Oncology 2018;29(2):445
    CrossRef
  5. Voncken FEM, Aleman BMP, van Dieren JM, Grootscholten C, Lalezari F, van Sandick JW, Steinberg JD, Vegt E. Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer. Strahlentherapie und Onkologie 2018;194(2):156
    CrossRef
  6. Larue RTHM, Klaassen R, Jochems A, Leijenaar RTH, Hulshof MCCM, van Berge Henegouwen MI, Schreurs WMJ, Sosef MN, van Elmpt W, van Laarhoven HWM, Lambin P. Pre-treatment CT radiomics to predict 3-year overall survival following chemoradiotherapy of esophageal cancer. Acta Oncologica 2018;57(11):1475
    CrossRef
  7. Davidson M, Chau I. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Review of Anticancer Therapy 2018;18(4):327
    CrossRef
  8. Liw P, Wen Y, Tsai C, Chang H, Tseng C, Hung T, Chao Y. Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy. The Journal of Thoracic and Cardiovascular Surgery 2018;155(5):2233
    CrossRef
  9. Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, Biermann K, van der Gaast A, van Hillegersberg R, Hulshof MCCM, Krishnadath KK, Lagarde SM, Nieuwenhuijzen GAP, Oostenbrug LE, Siersema PD, Schoon EJ, Sosef MN, Steyerberg EW, van Lanschot JJB, Doukas M, Krak NC, Poley J, van Rij CM, Bergman JJ, Gisbertz SS, van Laarhoven HW, Meijer SL, Goense L, Haj Mohammad N, Hobbelink MG, Offerhaus GJA, Vleggaar F, Curvers WL, Creemers G, Roef MJ, van der Sangen MJ, Buijsen J, Riedl RG, Schreurs WM, Warmerdam FA, Janssen M, van der Post C, Radema SA, Rosman C, Rütten H. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. The Lancet Oncology 2018;19(7):965
    CrossRef
  10. Chao Y, Chuang W, Yeh C, Chang H, Tseng C. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy. European Journal of Cardio-Thoracic Surgery 2018;53(1):201
    CrossRef
  11. van Olphen SH, Biermann K, Shapiro J, Wijnhoven BPL, Toxopeus ELA, van der Gaast A, Stoop HA, van Lanschot JJB, Spaander MCW, Bruno MJ, Looijenga LHJ. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy. Annals of Surgery 2017;265(2):347
    CrossRef
  12. Chao Y, Wen Y, Chang H, Tseng C, Liu Y. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. European Journal of Surgical Oncology 2017;43(12):2366
    CrossRef
  13. Arnett AL, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL. Utility of 18 F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. Journal of Thoracic Oncology 2017;12(1):121
    CrossRef
  14. Noordman BJ, Wijnhoven BPL, Lagarde SM, Biermann K, van der Gaast A, Spaander MCW, Valkema R, van Lanschot JJB. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Diseases of the Esophagus 2017;30(12):1
    CrossRef
  15. Contino G, Vaughan TL, Whiteman D, Fitzgerald RC. The Evolving Genomic Landscape of Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroenterology 2017;153(3):657
    CrossRef
  16. Klevebro F, Ekman S, Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer – Review article. Surgical Oncology 2017;26(3):290
    CrossRef
  17. Kathiravetpillai N, Koëter M, van der Sangen M, Creemers G, Luyer M, Rutten H, Nieuwenhuijzen G. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. European Journal of Surgical Oncology (EJSO) 2016;42(8):1183
    CrossRef
  18. Chao Y, Chang H, Tseng C, Liu Y, Wen Y. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. Diseases of the Esophagus 2016;
    CrossRef
  19. Heneghan HM, Donohoe C, Elliot J, Ahmed Z, Malik V, Ravi N, Reynolds JV. Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?. Annals of Surgery 2016;264(5):831
    CrossRef
  20. Noordman BJ, Wijnhoven BPL, van Lanschot JJB. Optimal surgical approach for esophageal cancer in the era of minimally invasive esophagectomy and neoadjuvant therapy. Diseases of the Esophagus 2016;29(7):773
    CrossRef
  21. Chao Y, Chang Y, Yeh C, Chang H, Tseng C, Chuang W. Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. British Journal of Surgery 2016;103(13):1874
    CrossRef
  22. Goense L, van Rossum PS, Kandioler D, Ruurda JP, Goh K, Luyer MD, Krasna MJ, van Hillegersberg R. Stage-directed individualized therapy in esophageal cancer. Annals of the New York Academy of Sciences 2016;1381(1):50
    CrossRef
  23. van Rossum PS, Goense L, Meziani J, Reitsma JB, Siersema PD, Vleggaar FP, van Vulpen M, Meijer GJ, Ruurda JP, van Hillegersberg R. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2016;83(5):866
    CrossRef
  24. Larue RTHM, Van De Voorde L, Berbée M, van Elmpt WJC, Dubois LJ, Panth KM, Peeters SGJA, Claessens A, Schreurs WMJ, Nap M, Warmerdam FARM, Erdkamp FLG, Sosef MN, Lambin P. A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer 2016;16(1)
    CrossRef
  25. Wong IY, Law S. Surgery in the era of neoadjuvant therapy for cancer of the esophagus. Esophagus 2016;13(2):105
    CrossRef
  26. Luo L, Zhao L, Wang Y, Tian X, Xi M, Shen J, He L, Li Q, Liu S, Zhang P, Xie D, Liu M. Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. Scientific Reports 2015;5(1)
    CrossRef
  27. Jhala D. Cytology of the gastrointestinal tract: opportunities to be tapped. Diagnostic Histopathology 2015;21(12):462
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/resprot.4320)

:
  1. Boshier PR, Wirsching A, Low DE. A Mastery Approach to Complex Esophageal Diseases. 2018. Chapter 13:165
    CrossRef
  2. Chiapponi C, Leers J, Schröder W, Bruns C. Evidenzbasierte Viszeralchirurgie maligner Erkrankungen. 2018. Chapter 2:35
    CrossRef
  3. van den Berg JW, Lagarde SM, Wijnhoven BPL, van der Gaast A, van Lanschot JJB. Minimally Invasive Surgery for Upper Abdominal Cancer. 2017. Chapter 4:33
    CrossRef